Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Amgen Inc.

Several ratings on Amgen Inc. were adjusted last week following a company meeting with analysts at which the company said it plans to use its excess cash flow to repurchase shares at the rate of $250 million

Read the full 388 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers